Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the U.S. Food and Drug
This revolutionary platform empowers scientists in the pharmaceutical industry to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput ligand-protein interaction prediction.
QVM149 is a combination of indacaterol acetate, glycopyrronium bromide and mometasone furoate, which was delivered with the dose-confirming BreezhalerIGB gas pipeline inhalation device during the mid-stage trials. The
Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The
The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as the expiration of the waiting
These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference. The trial compared Symbicort Turbuhaler with
Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in
Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 study did not meet primary endpoint of
The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). With more than 400 employees, the
The latest approval for Fragmin is for the blood thinner to be used for reducing symptomatic venous thromboembolism (VTE) in pediatric patients, aged one month and older. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.